SOX 和 XELOX 在进展期胃癌新辅助化疗中的临床疗效比较

摘要

Objective To investigate the clinical efficacy of SOX and XELOX in neoadjuvant chemo-therapy for advanced gastric carcinoma .Methods Seventy-five cases with advanced gastric carcinoma were se-lected from our hospital from Feb 1,2011 to Oct 1,2015.SOX and XELOX were used to these patients treatment . The relationship between SOX and XELOX with tumor stage ,clinical curative effect evaluation ,operation ,postop-erative pathology ,adverse reaction ,survival analysis with advanced gastric carcinoma had been analyzed retrospec -tively.Results The efficacy of SOX and XELOX were 47.22%,41.03%.Compared with the two groups ,the CT curative effect evaluation,effective rate,disease control rate had no significant differences (P>0.05).The median survival time of DFS and OS were significant between the two groups (P<0.05).Conclusion The SOX and XELOX for neoadjuvant chemotherapy of advanced gastric carcinoma treatment is safety and effective , and the XELOX is better than SOX in terms of long -term effect,prognosis and clinical benefits .%目的：探讨SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效。方法选取2011年2月1日—2015年10月1日我院行SOX和XELOX新辅助化疗的胃癌患者75例。分析两种方案临床分期、疗效评价、手术情况、术后病理、不良反应、生存分析等情况。结果 SOX和XELOX有效率分别为47．22％和41．03％。两组在CT疗效评价、有效率、疾病控制率方面比较，差异均不具有统计学意义（ P＞0．05）；两组DFS、OS中位生存时间，差异均具有统计学意义（P＜0．05）。结论 SOX和XELOX对进展期胃癌进行新辅助化疗均具有较高的安全性和有效性，XELOX远期疗效要优于SOX，改善患者预后。